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The NO/cGMP signaling cascade plays a pivotal role in regulation of the cardiovascular system. The relaxation of vascular smooth muscle cells is one key mechanism by which NO-driven cGMP elevation is reducing blood vessel tone. Therefore, stimulators of the soluble guanylate cyclase (sGC stimulators), which significantly stimulate cGMP production, can cause a dose-dependent relaxation of blood vessels with impact e.g. on pulmonary hemodynamics. The sGC stimulator riociguat can e.g. reduce pulmonary artery pressure and is approved for the treatment of pulmonary hypertension (PAH/CTEPH). In recent years, it became obvious that the second messenger molecule cGMP does not only induce smooth muscle cell relaxation but might also target a variety of other cells and tissues and could also influence tissue remodeling and fibrosis. Therefore, the application of cGMPincreasing sGC stimulators and sGC activators might have a substantially broader treatment potential with additional therapeutic applications also for the treatment of fibrotic diseases. Given the potential antifibrotic mode of action of sGC stimulators, we investigated if sGC stimulators could become a potential treatment option for Systemic Sclerosis (SSc). SSc is a connective tissue disease, characterized by excessive skin fibrosis, but also fibrosis of internal organs as lungs and kidneys, causing a high morbidity and increased mortality. There is still a significant unmet medical, especially for approved antifibrotic treatments since only symptomatic treatment options and treatment recommendations are currently available.
The sGC stimulators BAY 41-2272 and BAY 63-2521 (riociguat) were profiled in vitro and in vivo in preclinical models of SSc and skin fibrosis. In vitro, the sGC stimulators reduced collagen production in human dermal fibroblasts, reduced fibroblast-to-myofibroblast differsignaling. In vivo, the sGC stimulators prevented TGFß-induced skin fibrosis, prevented skin fibrosis in the bleomycin model, reduced skin fibrosis in the genetic tight skin (TSK-1) mouse model, reduced skin and intestinal fibrosis in the chronic graft versus host disease (cGvHD) mouse model and promoted wound healing in TSK-1 mice. These in vivo effects were seen at dosages which do not cause prohibitive blood pressure lowering effects. In summary, these preclinical results demonstrated in a broad set of animal models for SSc and skin fibrosis with various etiologies, a dose-dependent regression of skin fibrosis and improvement of wound healing. These data therefore, suggested to further explore the treatment potential of the sGC stimulator riociguat in SSc patients. Currently a randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat in patients with Systemic Sclerosis (dcSSc), RISE-SSc, is ongoing (NCT02283762). Background: Therapies which restore cyclic GMP (cGMP) levels within the kidney are hypothesized to slow disease progression. We evaluated the effects of BI703704, a soluble guanylate cyclase (sGC) activator, EX76637, a sGC stimulator, and EX77619, a phosphodiesterase type 5 (PDE5) inhibitor on the progression of diabetic nephropathy in obese ZSF1 rats.
Methods:
Male ZSF1 rats, implanted with telemetry devices, were treated with either BI703704 at 2 mg/kg, EX76637 at 1 or 3 mg/kg, or EX77619 at 5 or 15 mg/kg for 10 weeks, during which mean arterial pressure (MAP) and urinary protein excretion (UPE) were determined. At study end, glomerular and renal interstitial lesions were assessed. Alpha smooth muscle actin (α-SMA, a marker of myofibroblast activation) and p57 (a marker of podocyte health) were determined by immunohistochemistry. Renal cGMP levels were quantified as a measure of target engagement. Results: By Week 10, similar reductions in MAP were achieved (~8 mmHg) across treatment groups vs. vehicle. In parallel, sGC activation resulted in significant reductions in UPE (-31% vs veh), while there was no significant effect of EX76637 (+4% at 1 mg/kg; -16 % at 3 mg/kg vs veh), or EX77619 (-15% at 5 mg/kg; -9% at 15 mg/kg vs veh). Importantly, the effects of BI703704 on UPE were accompanied by reductions in the incidence of glomerulosclerosis (-21% vs veh), while neither EX76637 nor EX77619 was effective. In addition, interstitial lesions were modestly reduced by BI703704 (-13 % vs veh) and EX77619 (-18% vs veh). α-SMA was reduced by BI703704 (-27% vs veh) and EX76637 (-8% vs veh), while p57 was significantly increased by BI703704 (+11% vs veh) but not by EX76637 or EX77619. Importantly, target engagement was confirmed for EX77619.
Conclusions:
Despite similar effects on MAP, BI703704 was superior to EX76637 or EX77619 in reducing proteinuria and preventing renal damage in kidneys of ZSF1 rats.
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Identification and characterization of positive allosteric modulators of the natriuretic peptide receptor-A Henriette Andresen 1,2 , Lise Román Moltzau 1, 3 , Alessandro Cataliotti 2,3 , Finn Olav Levy cardioprotective mechanisms are clear. We herein assessed whether beneficial effects of the cGMP pathway in the cardiomyocyte require voltage and Ca 2+ -activated K + channels of the BK-type to oppose the myocardial damage during in vivo I/R injury. The authors declare no conflict of interest.
The cGMP-dependent protein kinase G I (PKGI) opposes cardiac hypertrophy and dysfunction, and PKGI-activating drugs remain under investigation for the treatment of heart failure. The downstream mechanisms through which PKGI promotes cardioprotection remain incompletely understood, suggesting that identifying PKGI substrates may reveal novel therapeutic targets in the treatment of cardiovascular disease. We previously identified the PKGI leucine zipper (LZ) binding domain to be a critical regulator of cardiac remodeling in response to cardiac pressure overload, and therefore sought to explore PKGI LZ binding substrates as novel cardioprotective molecules. Here we investigated one candidate PKGIα substrate in the myocardium, Mixed Lineage Kinase 3 (MLK3), an upstream regulator of stress-responsive JNK signaling. We first observed protein-protein interaction of endogenous PKGIα and MLK3 in myocardium by coimmunoprecipitation (n=5). Direct PKGIα-MLK3 interaction was confirmed with affinity purified proteins (n=4). In primary cardiomyocytes MLK3 mediated cGMP-stimulated JNK phosphorylation (n=3), and pharmacological MLK3 kinase inhibition induced cardiomyocyte hypertrophy (n=4, +27.0%). MLK3 protein expression was detected in human hearts, increased in myocardium from patients with both nonischemic and hypertrophic cardiomyopathy (MLK3/GAPDH: non-ischemic: 6.26 ADU ± 0.85, n=9, hypertrophic: 6.97 ADU ± 1.42, n=8), and in hearts of mice subjected to cardiac pressure overload (n=8, +138.0%). MLK3 knockout mice (MLK3 -/-) exhibited baseline cardiac hypertrophy with preserved cardiac function and structure. In response to pressure overload, MLK3
-/-mice developed accelerated cardiac dysfunction as measured by invasive hemodynamics (n=5-8, LV ejection fraction, dP/dT max, dP/dT min, and LV end diastolic pressure) compared to MLK3 +/+ littermate controls. Pressure overloaded MLK3 -/-hearts had increased hypertrophic (ANP) and fibrotic (Col1a1) gene expression changes in the heart (n=3-6) suggesting accelerated cardiac remodeling. Mechanistically, pressure overloaded MLK3 -/-mice exhibited selective impairments in myocardial JNK activation, with no change in activation of other MAPK proteins. Together these data demonstrate MLK3 is a novel PKGIα substrate, MLK3 inhibits adverse cardiac remodeling in vivo, and suggests regulation of myocardial JNK signaling may underlie the cardioprotective actions of MLK3. This study further supports the approach of exploring myocardial PKGI-substrates to identify novel cardioprotective molecules.
). Annual US healthcare costs of obesity exceed $150 billion, and by 2030 will exceed 20% of those costs. Obesity reflects over-nutrition, in which calories eaten exceed those expended metabolically, in part reflecting dysregulated satiety responses controlling appetite. Beyond the established cardiovascular and metabolic sequelae contributing to this morbidity and mortality, there is an established relationship between body mass and the risk of cancer, including colorectal cancer. Indeed, obese patients have~20-60% greater risk of, and~2-fold higher death rate from, colorectal cancer. Although the epidemiology of this relationship is well-established, the precise molecular mechanisms connecting obesity and colorectal cancer remain to be defined. GUCY2C is the receptor for the paracrine hormones guanylin in the colorectum and uroguanylin in small intestine. An emerging paradigm suggests that guanylin loss disrupting the GUCY2C paracrine signaling axis, and epithelial cell homeostasis, is a required step in colorectal cancer initiation. Separately, secretion of uroguanylin into the circulation by the small intestine forms a gut-brain endocrine axis controlling hypothalamic GUCY2C regulating satiety and appetite linked to body mass and metabolic homeostasis. Here, we reveal that over-nutrition and consumption of excess calories suppresses guanylin and uroguanylin expression, simultaneously disrupting GUCY2C paracrine and endocrine signaling axes at the nexus of obesity and colorectal cancer. Expression of uroguanylin and guanylin, but not GUCY2C, is reduced in small and large intestine, respectively, by diet-induced obesity in mice and humans. Hormone expression appears to be reversibly suppressed by ingested calories through endoplasmic reticulum stress. In that context, transgenic replacement of guanylin in intestine eliminates tumorigenesis induced by obesity. Further, transgenic expression of uroguanylin in brain improves satiety responses dysregulated in obesity. These observations suggest a novel pathophysiological model in which caloric suppression of guanylin and uroguanylin silencing GUCY2C is at the intersection of molecular mechanisms underlying obesity and its associated risk of colorectal cancer. Moreover, they reveal a correlative therapeutic paradigm which leverages the preservation of GUCY2C expression in over-nutrition, in which hormone supplementation reconstitutes endocrine and paracrine axes to restore appetite control opposing obesity and intestinal epithelial cell homeostasis preventing tumorigenesis, respectively.
References: [1] . JE Lin, F Colon-Gonzalez, E Blomain, GW Kim, A Aing, B Stoecker, J Rock, AE Snook, T Zhan, T Hyslop, M Tomczak, RS Blumberg, SA Waldman: Calories suppress guanylin silencing the GUCY2C tumor suppressor in colorectal cancer in obesity. Can. Res. 2016, 76:339-346 [2] . GW Kim, JE Lin, AE Snook, A Aing, DJ Merlino, P Li, SA Waldman: Calorieinduced ER stress suppresses uroguanylin satiety signaling in dietinduced obesity. Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxide signaling pathway, is formed as a heterodimer by various isoforms of its α and β subunit. sGC is the physiological receptor for nitric oxide (NO) and NO-releasing drugs. Its activation induces the synthesis of the second messenger cGMP. cGMP regulates the activity of various downstream proteins, leading to vascular relaxation, inhibition of platelet aggregation, and modified neurotransmission. Recently, genomic studies -genome-wide association studies (GWAS) in large samples of unrelated probands and exome-sequencing studies (WES) in extended families presenting with myocardial infarction -revealed the importance of rare and common genetic variation of sGC and other genes involved in NO-signalling, like NOS3, encoding the endothelial NO-synthase, and PDE5A, on cardiovascular risk. Understanding the full spectrum of phenotypic consequences of rare and common variants may provide insight into the benefits and risks of pharmacologic manipulation of nitric oxide signalling.
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The human platelet phosphoproteome after sGC stimulation by 
Background:
Platelets are circulating sentinels of vascular integrity and are activated, inhibited or modulated by multiple hormones, vasoactive substances or drugs. Endothelium-or drug-derived NO strongly inhibits platelet activation via activation of the soluble guanylyl cyclase (sGC) and cGMP elevation, often in synergy with the cAMP-elevating prostacyclin. However, the molecular mechanisms and diversity of cGMP effects in platelets are poorly understood and sometimes controversial. Recently, we established the quantitative human platelet proteome 1 , the Iloprost/prostacyclin/cAMP/PKA affected phosphoproteome 2 , the interaction of the ADP and Iloprost/prostacyclinaffected phosphoproteome 3 and the effects of Riociguat on human platelets 4 . Here, the aim was to establish and analyze the phosphoproteome after selective stimulation of the sGC/cGMP pathway by Riociguat in human platelets.
Methods:
Phosphorylation and functional platelet effects of various NO donors (Sodium nitroprusside, DEA-NO, Sodium S-Nitrosocysteine) and the sGC stimulator Riociguat were compared. For the full phosphoproteomic study the effect of Riociguat (10 μM, 5 min) was investigated as the most robust and cAMP-independent cGMP-effector reagent in platelets and compared to the phosphoproteome of Iloprost (5 nM, 2 min)measured in parallel as described 2, 3 .
Results:
In total we quantified 8181 phosphorylation sites from 2249 proteins across three biological replicates. Riociguat increased (>1.5-fold up) and decreased (>1.5-fold down) phosphorylation levels in 345 and 94 proteins, respectively. The spectrum of proteins covers many platelet functions including membrane proteins/receptors, signaling molecules and granule proteins including 24 protein kinases (e.g. MYLK, CAMKK1/2, CDK16/17/18, BRAF) with increased and 4 protein kinases (KALRN, KSR2, PAK2, WNK1) with reduced levels. Comparison of the Riociguat phosphoproteome with the Iloprost (cAMP/PKA) phosphoproteome showed that there is a significant overlap of cGMP and cAMP responses at the level of protein phosphorylation but there are a number of proteins more strongly up-regulated by Riociguat. The top-list of Riociguat affected phosphoproteins include established PKG substrates (VASP, MYLK, ITPR1, PDE5A, MRVI1 and others) but also others previously not described as PKG substrates.
Conclusion:
This is the first description of the human platelet phosphoproteome affected by selective stimulation of the sGC/cGMP pathway. The magnitude and diversity of the Riociguat/cGMP phosphoproteome is extensive and significantly overlaps with the Iloprost/cAMP phosphoproteome. However, there are number of novel PKG substrates and some distinct differences between cAMP and cGMP pathway. The regulated phosphorylation of multiple protein kinases and signalling molecules by the cGMP/PKG system indicates a substantial network. −5 , and mean pulmonary arterial pressure >30 mmHg, despite PDE5i treatment for ≥90 days. Patients underwent a 1-3-day PDE5i treatment-free period before receiving riociguat individually adjusted up to a maximum of 2.5 mg three times daily. Concomitant endothelin receptor antagonists (ERAs) were allowed. Exploratory endpoints included change from baseline to Week 24 in 6MWD, WHO FC, N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and NO signaling-related and other biomarkers.
Results:
Sixty-one patients (mean±SD age 54±14 years; 74% female) were enrolled and 51 (84%) completed the study. Patients were pretreated with sildenafil (n=40 [66%]) or tadalafil (n=21 [34%]); 50 (82%) were taking concomitant ERAs at baseline. At Week 24, 6MWD and WHO FC were improved, plasma cGMP had increased, and NT-proBNP decreased compared with baseline ( Table 1) . Levels of cGMP and NT-proBNP correlated with PAH severity at baseline and Week 24. Sixteen patients (34% [n=47]) achieved the composite endpoint of no clinical worsening, WHO FC I/II, and ≥30 m increase in 6MWD. These patients had lower NT-proBNP and cGMP at baseline compared with those who did not achieve the composite endpoint. Serious adverse events occurred in 10 patients (16%), 2 of which (3%) were study drug-related. Conclusions: RESPITE demonstrated that riociguat improved WHO FC and 6MWD as well as decreasing NT-proBNP and increasing plasma cGMP levels among PAH patients who had an inadequate response to PDE5i. No new safety signals were observed. The study provides preliminary evidence that switching from PDE5i to riociguat may be beneficial in PAH patients who are not at treatment goal with PDE5i. Further studies are needed to confirm if biomarker levels may help identify patients who would benefit from switching to riociguat.
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The soluble guanylate cyclase stimulator, IW-1973 
Introduction:
Non-alcoholic steatohepatitis (NASH), characterized by liver fibrosis, inflammation, and steatosis, increases a patient's risk for developing cirrhosis. IW-1973, a novel soluble guanylate cyclase stimulator enhances signalling through the nitric oxide-sGC-cGMP pathway and has demonstrated effects on blood flow, inflammation and fibrosis in a variety of tissues in multiple animal models. The aim of this study was to assess the effects of IW-1973 in rodent models of NASH and fibrosis. Methods: IW-1973 effects on TGFβ induced α-SMA expression were measured in rat liver stellate cells. The effects of acute and chronic dosing of IW-1973 on liver cGMP production and pVASP were determined in normal rats. To test the effects of IW-1973 in NASH and fibrosis, two murine models were used. In the MCD model, mice were fed a methionine and choline deficient high-fat diet and continually dosed for 9-weeks with IW-1973 at 1 and 3 mg/kg/day. In the STAM model, IW-1973 was administered therapeutically at 1.5,3 and 10 mg/kg/day. The Thioacetamide (TAA)-induced liver fibrosis model was used with rats; IW-1973 was dosed therapeutically at 1,3 and 10 mg/kg. Fibrosis was analysed using histological and immunohistochemical staining. Inflammation and fibrosis gene expression profiles were performed in livers using b-DNA technology. 
Background:
Studies over the last decade have investigated the function of nitric oxide (NO) in the cochlea. NO activates the NO-sensitive guanylate cyclase and triggers intracellular signal transduction pathways involving cGMP. For cochlear hair cells, the role of NO-mediated cascades is controversial, with studies predicting a protective or detrimental potential. We examine here the cochlear function of mice lacking one of the two NO-sensitive guanylate cyclase isoforms (NO-GC1 KO or NO-GC2 KO). The deletion of NO-GC1 or NO-GC2 did not influence electromechanical outer hair cell (OHC) properties, measured by distortion product otoacoustic emissions (DPOAEs), neither before nor after noise exposure, nor were click or noise burst-evoked auditory brainstem responses (ABR) thresholds different from controls. Yet, inner hair cell (IHC) ribbons and auditory nerve responses were significantly less deteriorated in NO-GC1 KO and NO-GC2 KO mice after noise exposure. Consistent with a selective role of NO-GC in IHCs, NO-GC β1 mRNA is present in isolated IHCs but not in OHCs. Using transgenic mice expressing the FRETbased cGMP biosensor cGi500, NO-induced elevation of cGMP was detected in real-time in IHCs but not in OHCs. Importantly, longterm treatment with NO-GC stimulants led to a decline of auditory nerve response without change in OHC function in older but not younger animals. It is now accepted that inorganic nitrate, through its sequential chemical reduction to nitrite and then to nitric oxide (NO), provides a source of NO in the body that exerts a number of important actions upon the cardiovascular system including blood pressure lowering; effects that are mediated by cyclic GMP (cGMP). Whilst the second step of this process is due to the activity of mammalian nitrite reductases, including xanthine oxidoreductase, the former (i.e. the chemical reduction of nitrate to nitrite) is critically dependent upon the activity of commensal bacteria, particularly residing within the oral cavity. We and others have speculated that the entero-salivary circuit of inorganic nitrate offers an opportunity to target NO/cGMP signalling in the cardiovascular system in disease via a pathway that circumvents the classical, but dysfunctional, L-arginine/NO synthase (NOS) pathway. This proposal stems from observations indicating that supplementation of inorganic nitrate via dietary means (vegetables, particularly green leafy vegetables have a high inorganic nitrate content) or through nitrate salt administration exerts blood pressure lowering, anti-inflammatory and anti-thrombotic effects in patients with cardiovascular disease. In addition, evidence suggests that dietary inorganic nitrate not only provides beneficial effects acutely but that these positive actions are sustained with chronic administration and do not suffer tachyphylaxis. This difference in pharmacokinetics intimates that unlike the organic nitrates, inorganic nitrate provides sustained NO delivery with persistent administration and thus provides an approach to NO delivery that might prove useful in the therapeutics of chronic disease. In this presentation, the circuit for bioactivation of inorganic nitrate in the body and the key role that bacteria play in this process will be addressed. In addition, clinical studies supporting a role for nitrate bioactivation in setting blood pressure, and the potential for use of this circuit in the therapeutics of cardiovascular disease will be described.
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From Heaven to Heart: Nitroxyl (HNO) Actions in the Cardiovascular System Nazareno Paolocci 1,2 (npaoloc1@jhmi.edu) Reactions based on the transfer of one or more electrons from a donor (reductant) to an acceptor (oxidant) account for many physiologically relevant cellular processes. Both reactive oxygen (ROS) and nitrogen species (RNS) can signal through these reduction/oxidation (redox) reactions, particularly via reversible interaction with reactive thiols, namely cysteines. Nitroxyl (HNO) -the one-electron reduction product of nitric oxide (NO . ) -has garnered a lot of attention owing to its pharmacological properties that are quite dissimilar from those exhibited by its sibling NO . or other RNS such as nitrite/nitrate. HNO uniqueness stands out especially in the cardiovascular system, where it exerts positive effects on contractility and relaxation, while inducing venous and arterial dilation. These benefits are preserved in failing hearts that harbour altered redox conditions and perturbed signalling pathways, such as cAMP/PKA. In fact, there are, at least, four biochemical properties that single HNO out from other modulators of myocardial function, justifying its potential both as a signalling molecule and therapeutic option. They are its elective, and likely selective thiophilic nature, inertness towards ROS, modest reactivity with molecular O 2 , and likely the fact that HNO does not interfere with other posttranslational modifications, such as phosphorylation. Accordingly, HNO donors are currently evaluated for safety and efficacy in patients with acute decompensated heart failure (ADHF). Notwithstanding, many key questions still surround HNO biology and pharmacology. First and foremost, it is still unclear under which conditions, and where HNO is formed in the human body (although it is a major gas in the space!).
Equally unknown is what mechanisms eventually cease its signalling, along with the exact chemical nature of HNO-induced modifications that pave the way to either signalling or detrimental effects. Finally, much remains to be discovered in terms of additional HNO biological actions that may dovetail nicely with already established effects in the circulation as well as in other compartments. Here, major "knowns" and "unknowns" about HNO biology and HNO donor pharmacology will be discussed, and the HNO therapeutic portfolio for ADHF will be compared to current mainstay therapies.
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Dr. Nazareno Paolocci is scientific founder and stock-holder at Cardioxyl Pharmaceuticals, Inc./Bristol-Myers Squibb. Protein kinase G (PKG) is subject to complex redox regulation involving several modes of oxidation, including interprotein disulfide formation at C42. The C42 disulfide homodimer is associated with targeting and activation of PKG Iα, which significantly contributes to vasodilation and blood pressure lowering in response to exogenously applied or endogenously generated oxidants. Interdisulfide-PKG Iα levels were found to increase in the mouse heart during diastolic stretch, consistent with evidence that oxidants are produced during myocardial relaxation at this time. Interdisulfide-PKG Iα selectively targets and phosphorylates phospholamban at S16, which activates the sarcoplasmic reticulum (SR) Ca 2+ ATPase 2a (SERCA2a) to enhance sequestration of calcium into the sarcoplasmic reticulum. Consistent with this C42S PKGIα knock-in (KI) mice that are resistant to kinase oxidation to the interdisulfide state are hypertensive and have diastolic dysfunction as evidenced by echocardiography and left ventricular Pressure-Volume catheter analysis. Thus, it is evident that PKG Iα interprotein disulfide formation occurs during myocardial stretch, and without this mechanism the hearts have impaired relaxation during diastole. Given the role for interdisulfide-PKG Iα in blood pressure-lowering, we assembled and screened a 'soft-electrophile' compound library for molecules that would mimic or induce oxidation of the kinase. We identified a compound which we have called G1 which induces vasodilation of isolated arterial vessels from wild type mice, whereas the impact on vessels from KI was significantly deficient. G1 also lowered blood pressure in an angiotensin II-induced hypertension model in wild type, but not KI, mice. This provides proofof-principle for a new class of anti-hypertensive drugs, which conceptionally may also have value in the treatment of diastolic heart failure. 
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Redox regulation of G-kinase
Background:
As a primary receptor of cGMP in mammalian cells, PKG is a central mediator of the NO-cGMP signaling pathway that regulates crucial physiological processes [1] [2] [3] . These include smooth muscle tone, bone growth, nociception, and memory formation. Two types of PKGs exist, PKG I and II. They display distinct subcellular localization, tissue expression, and substrates suggesting their non-redundant cellular functions [4] . Cyclic GMP analogs, 8-Br-cGMP, 8-pCPT-cGMP, and PET-cGMP, have been widely used for characterizing cellular functions of PKG I and II isotypes [5, 6] . However, interpreting results obtained using these analogs has been difficult due to their low isotype specificity. Additionally, the regulatory (R)-domain of each isotype has two binding sites with different cGMP and analog binding characteristics [7] , making understanding the molecular basis for isotype specificity of these compounds even more challenging.
Results:
To determine isotype specificity of cGMP analogs and their structural basis, we generated the full-length regulatory domains of PKG I and II with each binding site disabled, determined their affinities for these analogs, and obtain co-crystal structures of both isotypes bound with cGMP analogs. To disable each site for cGMP binding, we replaced a conserved glycine within each cGMP binding pocket (G182 and G306 in PKG I and G232 and G356 in PKG II, respectively) with a glutamate. These mutations are predicted to cause steric hindrance and charge repulsion with the negatively charged cyclic phosphate moiety. Our affinity and activation measurements using competitive surface plasmon resonance and microfluidic mobility-shift assay show that PET-cGMP and 8-pCPT-cGMP are~40-50 fold selective in binding and~10 fold in activating against each isotype, whereas 8-Br-cGMP is only~10 fold selective in binding and~4 fold in activating PKG II. 8-Br-cGMP and 8-pCPT-cGMP similarly bind and activate PKG I compared to cGMP (Tables 2). In contrast, 8-Br-cGMP and 8-pCPT-cGMP show gradual increases in both EC 50 and K A values for PKG II. Unexpectedly, PET-cGMP binds and activates PKG II with similar potencies as cGMP, providing little selectivity against PKG II (Tables 2) The site-specific mutant data using competitive surface plasmon resonance suggest that the B-sites provide the high preference of PET-cGMP in PKG Iβ and the structures of the PKG I and II CNB-B domains explain why. The crystal structure of PKG I CNB-B domain bound with PET-cGMP shows that PET-cGMP interacts with its more open pocket and forms a unique π/π interaction with Arg285 at β4 (Fig. 1 ). On the other hand, our structures of PKG II CNB-B show a more shielded pocket due to the C-terminal helix (αC-helix) that provides the most of the cGMP specific contacts (Fig. 1 ).
In particular, our model of the PKG II CNB-B docked with PET-cGMP shows that Gln335 at the analogous position to Arg285 of PKG I and Asp412 at the αC-helix causes steric clashes with the PET moiety reducing its affinity for the B-site [8] . Lastly, the site-specific mutant data also suggest that the A-sites are mainly responsible for the high preference of 8-pCPT-cGMP in PKG II and the crystal structures of the CNB-A domains explain why. Our structures of the CNB-A domains of PKG I and II show that PKG II has a larger β5/β6 hydrophobic pocket that can better accommodate a bulky functional group compared to PKG I, which explains its lower EC 50 value [8, 9] .
Conclusion:
Our structural and functional results explain selectivity of these analogs for PKG I and II and provide a starting point for the rational design of isotype selective activators.
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The authors declare no conflict of interest. Biological background: Mycobacterium tuberculosis escapes killing in human macrophages by secreting protein kinase G (PknG), which intercepts host signaling to prevent the fusion of the phagosome engulfing the mycobacteria with the lysosome. The N-terminal~75 residues were predicted to show no regulatory secondary structure (NORS, not present in the crystal structure shown in Fig. 2 ) but to harbor the major in vivo phosphorylation site (T63) and to play a role for PknG regulation by autophosphorylation in trans. The following rubredoxin-like metalbinding motif (RD,~74-147, Fig. 2 ) makes tight interactions with the catalytic domain (~148-420) and mediates PknG redox regulation. Deletions or mutations in the NORS or the redox-sensitive RD significantly decrease PknG survival function.
Results and Conclusion:
Here, we present nuclear magnetic resonance (NMR) spectroscopy, in vitro kinase assay, and molecular dynamics (MD) simulation data that provide novel insights in the regulatory roles of the NORS and the RD. The NORS region is rather dynamic and appears indeed to be natively disordered. In agreement with published data, we observe autophosphorylation only if the NORS region is present and thus in the NORS region. Phosphorylation in the 
Activation Constant Measurements of PKG I and II Full Lengths
Footnote: EC 50 and K A values were measured using competitive surface plasmon resonance and microfluidic mobility shift assay. (n) = Number of measurements. NORS results only in local conformational changes and does not induce interactions with the following RD. In the crystal structure ( Fig. 2) , the reduced, metal bound RD makes tight interactions with the catalytic domain. Based on NMR structural data, it can also fold in its absence. The combined NMR-, MD-, and kinase assay data further suggest that oxidation-induced unfolding of the RD regulates substrate access to the catalytic domain and thereby PknG function under different redox conditions, e.g. if exposed to increased levels of reactive oxidative species (ROS) in host macrophages [2] . We further analyzed the interactions of the RD with membrane mimetics. Both, the reduced, metal bound and the oxidized unfolded RD, can interact with micelles and bicelles, but not liposomes. This may play a role for the observed membrane localization of PknG.
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References: [1] . N Scherr, S Honnappa, G Kunz, P Mueller, R Jayachandran, F Winkler, J Pieters, MO Steinmetz: Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis. Background: Pulmonary hypertension (PH) is a disease of the vasculature of the airways resulting in vasoconstriction and arterial remodelling, eventually leading to right ventricle failure and death. cGMP-dependent protein kinase (PKG) I knock-out mice develop spontaneous PH, while PKG I protein expression is paradoxically upregulated during hypoxic PH. Previous work from this laboratory has shown PKG Iα is susceptible to oxidation, forming a disulfide homodimer associated with targeting and activation of the kinase that mediates vasodilation and blood pressure lowering. During acute hypoxia, pulmonary cells become pro-reducing -which may be anticipated to reduce the amount of disulfide-PKG Iα and so contribute to acute hypoxic pulmonary vasoconstriction. In the present study, we investigated the redox state of pulmonary PKG Iα during chronic hypoxia and its potential role in pathogenesis of hypoxic PH. Results and Discussion: Mice were subjected to hypoxia (10% O 2 ), which caused oxidation of lung PKG Iα as determined at 3 or 28 day time points compared to basal normoxic levels. The H 2 O 2 -producing enzymes NADPH oxidase 4 (NOX4) and extracellular superoxide dismutase (SOD3) were also increased in the lungs as measured at the 28 day time point, thus potentially contributing to PKG Iα oxidation. In addition, the vascular isoform of cystathionine gamma-lyase (CSE), which produces the vasorelaxant H 2 S, was also upregulated at both time points of Fig. 2 (Abstract A20). The crystal structure of Mycobacterium tuberculosis protein kinase G from residues 74-750 [1] . The redoxsensitive metal binding motif (RD) is shown in red, the catalytic serine/threonine kinase domain (KD) in complex with a small molecule inhibitor in yellow and blue, respectively, and the Cterminal tetratricopeptide repeat domain (TPRD) in green hypoxia. These observations are consistent with PKG Iα oxidation being mediated by H 2 O 2 -induced oxidation of H 2 S, which generates pro-oxidising polysulfide species. Interestingly, we observed increased PKG Iα oxidation, as well as NOX4 and CSE upregulation in lungs from patients with pulmonary arterial hypertension. This suggests that kinase oxidation pathway may be important in the etiology of PH in humans. To dissect the potential role of oxidised PKG Iα in hypoxic PH we utilised redox dead Cys42Ser PKG Iα knock-in (KI) mice which are resistant to oxidation. We found that the KI mice had increased pulmonary vascular resistance, elevated pulmonary myosin light chain phosphorylation, as well as potentiated right ventricular hypertrophy and higher right ventricular pressure after 4 weeks of chronic exposure to hypoxia, as compared to their WT littermates. These observations were consistent with U-46619-constricted pulmonary vessels from KI mice having impaired vasodilatory responses to H 2 O 2 compared to WT under normoxic condition, despite equal maximal constriction to the pressor agonist. Our finding suggests that chronic PKG Iα oxidation, as well as perhaps increased PKG expression, serves an important novel intrinsic adaptive mechanism to offset increased pulmonary pressure in PH and thus reduce RV after-load and so limit progression to right heart failure. Chronic pharmacological inhibition of CSE with propargylglycine (50 mg/kg/day) potentiated RV pressure and hypertrophy, as well as attenuated PKG Iα oxidation in the lung after 2 weeks of chronic hypoxic exposure. In contrast, chronic treatment with the H 2 S donor sodium hydrosulfide (23 mg/kg/day) or potassium polysulfide (2 mg/kg/day) prevented excessive RV pressure and hypertrophy after 2 weeks of hypoxia. Preliminary data from ongoing experiments suggest that this protection provided to WT mice by H 2 S or its oxidised variants was not afforded to the Cys42Ser PKG Iα KI. An unbiased microarray transcriptomic screen revealed an upregulation of pro-growth, extracellular matrix remodelling and endothelial to mesenchymal transition cellular signalling pathways in response to early hypoxia (day 3) in the lungs of the redox-dead KI mice compared to WT. Consequently, the KI mice showed excessive muscularisation of small pulmonary vessels and enhanced transition of pulmonary endothelial cells to myofibroblasts after 4 weeks of chronic hypoxia. Given the important role of PKG I in cell growth and cancer, these data suggest that hypoxia-induced PKG Iα oxidation may prevent pulmonary vascular smooth muscle cell proliferation and/or endothelial to mesenchymal cell transition, in addition to its pressure-lowering role.
Conclusion:
We conclude that hypoxia-induced NOX4, SOD3 and CSE upregulation may underlie PKG Iα oxidation in this scenario and thus could mediate endogenous adaptation to PH by inducing phosphorylation of target proteins involved in lowering pulmonary pressure, resulting in reduced RV afterload in the setting of PH. This mechanism could also be relevant to other situations in which occurs PH, including PAH in human. The redox dead PKG Iα KI mice lack this protective mechanism and therefore have an exacerbated hypoxic PH phenotype. Interventions inducing PKG Iα oxidation in the lung, such as H 2 S donors or drugs that induce the selective oxidation of PKG Iα, could be beneficial in the treatment and management of PAH.
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The authors declare no competing financial interests or potential conflict of interests. Background: Endothelium-derived C-type natriuretic peptide (CNP) plays a fundamental role in regulating vascular homeostasis by controlling arterial tone, blood pressure, leukocyte flux, platelet reactivity and the integrity of the vessel wall [1] . However, a physiological role for endogenous CNP in the heart remains to be established. Therefore, we have utilised two novel mouse strains with endothelium or cardiomyocyte -specific deletion of CNP to determine if the peptide modulates heart function under basal conditions and during cardiac stress.
Materials & Methods:
Blood pressure and electrocardiogram (ECG) were assessed by radiotelemetry. A Langendorff heart model was used to study coronary vascular reactivity and ischemia-reperfusion (I/R) injury ex vivo. Echocardiography was performed to determine cardiac function at baseline and following pressure overload (abdominal aortic constriction [AAC]; 6 weeks) -induced left ventricular hypertrophy/heart failure. Following AAC, cardiomyocyte hypertrophy and interstitial fibrosis were determined using immunohistochemistry and qPCR. A subset of experiments were also repeated in mice with global deletion of natriuretic peptide receptor C (NPR-C) to delineate the signalling pathway involved in mediating any cardiac effects of CNP.
Results:
Hearts from endothelium-specific CNP knockout (ecCNP KO) mice exhibited attenuated responses to the vasodilators bradykinin and acetylcholine compared to wildtype (WT) littermates. Shear-stress induced coronary dilatation (i.e. reactive hyperaemia) was also blunted in ecCNP KO. Larger myocardial infarct sizes and poorer recovery of left ventricular contractility were observed in hearts from mice lacking cardiomyocyte-derived CNP (cmCNP KO) following IR injury. Similar results were found in NPR-C KO mice but not ecCNP KO hearts. Under basal conditions heart rate, blood pressure and ECG parameters in cmCNP KO mice were not altered. However, during pressure overload-induced heart failure cmCNP KO mice exhibited greater cardiac dysfunction and fibrosis than WT littermates; a similar phenotype was apparent in NPR-C KO, but not ecCNP KO, animals subjected to AAC. Furthermore, infusion of CNP via an osmotic minipump reversed cardiac dysfunction following AAC in WT animals, but had no effect in NPR-C KO mice.
Conclusion:
These data suggest that both endothelial and cardiomyocyte -derived CNP play distinct but important roles in the heart, governing coronary vascular tone and the response to pressure overload. These protective functions are mediated, at least in part, via activation of NPR-C.
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The authors declare no conflicts of interest. We developed a recombinant adeno-associated virus (AAV) vectormediated gene supplementation therapy for the treatment of CNGA3-linked ACHM (ACHM2). The vector expresses full length human CNGA3 under control of the human, cone-specific cone arrestin promoter and was packaged with AAV8 capsid. The resulting vector (rAAV8.CNGA3) was tested for efficacy in the Cnga3 knockout (KO) mouse model of ACHM2. Toxicity and biodistribution was assessed in non-human primates (NHP). rAAV8.CNGA3 delivered into the subretinal space of Cnga3 KO led to efficient and stable CNGA3 transgene expression and biological activity as determined by immunohistochemistry and electroretinography, respectively. Up to 1x10 12 total vector genomes (vg) have proven save when delivered into the subretinal space of NHPs with only limited biodistribution and shadding and minimal signs of inflammation. An interventional phase I/II clinical trial (NCT02610582) was initiated focusing on safety and efficacy of a single subretinal injection of rAAV8.CNGA3 in patients with ACHM2 at three different doses: 1x10 10 , 5x10 10 , and 1x10 11 total vg.
Conclusions:
Although the approach was targeting the central retina and involved temporal detachment of the fovea/macula, the treatment has proven to be safe, was well tolerated and did not results in any clinically apparent inflammation or test item related events. Preliminary clinical data will be discussed. The accumulation of damaged/misfolded and consequently ubiquitinated proteins that are insufficiently cleared by the ubiquitin proteasome system (UPS) contributes to many diseases. However, therapeutic methods to enhance the UPS and counter proteotoxicity are lacking. Cardiac infarction is an example of a disorder where ubiquinated protein accumulation (UPA) is thought to play a pathophysiological role. In studies employing a model in which PKG activation is suppressed in vivo or in vitro, we found this accumulation and attendant myocardial or myocyte toxicity worsened. Activating PKG in a similar setting was beneficial. An unbiased cGMPstimulated phosphoproteome analysis in adult myocytes revealed Ser20 on carboxyl terminus of the Hsc70-interacting protein (CHIP) was a novel target of PKG activation. We found suppressing PKG activation results in reduced CHIP expression in the myocardium and in myocytes subjected to simulated ischemia. Using gain (S20E) and loss (S20A) of function phospho-mutants, we found S20E-CHIP mimicked PKG protection, reducing UPA and cytotoxicity with ischemia. The opposite occurred with S20A-CHIP. Intriguing, if S20A was expressed, PKG activation was unable to rescue the worsened phenotype, even though it can still act to blunt other signalling pathways including enhancement of proteasome protease activity. The molecular consequence of S20 phosphorylation was an increase of CHIP binding to its cognate chaperone Hsc70, and stabilization of posttranscriptional CHIP protein levels. Depressing PKG activity (or using the S20A mutant) dissociated CHIP from Hsc70, reduced its protein expression levels, and compromised its capacity to enhance protein quality control. These data identify PKG-CHIP interactions that control UPS activity, and provide a new therapeutic avenue to treat diseases with compromised protein quality control. In addition to its role as regulator of the chronotropic, inotropic and lusitropic response to catecholamines, cAMP affects multiple other functions including, among others, cell growth, metabolism and death. This complex functional role is achieved via modulation of ion fluxes at membranes and of myofilament sensitivity to Ca 2+ as well as via regulation of transcription factors and a variety of enzymes and other targets. A key question remains how coordination is achieved among the complex cAMP signalling networks. In recent years we [1] [2] [3] [4] [5] and others [6] [7] [8] have demonstrated that cAMP signalling is compartmentalised. Compartmentalised signalling allows individual GPCRs to generate distinct cAMP pools that, in turn, activate defined subsets of localized PKA that are tethered in proximity to specific targets via binding to A kinase anchoring proteins (AKAPs). Posphodiesterases (PDEs), a superfamily of enzymes that degrade cAMP and that includes more than 50 isoforms presenting unique regulation and subcellular localisation features, play a key role in the spatial regulation of cAMP propagation, and regulate cAMP levels within individual compartments. Thus, displacement of individual PDE isoforms from their subcellular anchor site results in local elevation of cAMP [5] . Compartmentalisation of cAMP signalling has important implications for cardiac physiology and pathophysiology [6] . We have recently demonstrated, for example, that inhibition of PDE2A, but not inhibition of PDE3 or PDE4, results in anti-hypertrophic effects both in vitro and in vivo [9] . The compartmentalised nature of cAMP signalling prompts the idea that with a detailed understanding of the organization, regulation and function of individual cAMP compartments it may be possible to target individual cAMP pools, rather than global intracellular cAMP levels, in order to achieve greater therapeutic efficacy and specificity [7] . The second messenger cGMP serves diverse functions in the cardiovascular and neuronal systems. FRET-based cGMP indicators derived from the cGMP-binding domains of the cGMP-dependent protein kinase I can be used to visualize cGMP signals in primary cells. However, expression of FRET-based cGMP indicators in primary cells is challenging. Therefore, we generated a knock-in mouse line with stable and ubiquitous expression of a FRET-based cGMP indicator (cGi500). This indicator with an EC50 for cGMP of 500 nM allows for the detection of cGMP concentrations between 100 nM and 3 μM. Using these mice, we analysed cGMP signals in primary neurons, cardiac cells (myocytes and fibroblasts) and renal glomeruli. In cardiac cells and renal glomeruli, nitric oxide-and natriuretic peptideinduced signals were compared and the phosphodiesterases responsible for cGMP degradation were identified. In hippocampal and cortical neurons, analysis of cGMP signals induced by glutamatergic agonists revealed that not only NMDA but also AMPA is able to increase cGMP via endogenous nitric oxide formation. Introduction: Cyclic guanosine 3´5´-monophosphate (cGMP) plays a crucial role in the regulation of multiple physiological processes including the cardiovascular system [1] . As a consequence of hypoxia in the heart, maladaptive signaling cascades are activated that can result in cardiac damage and finally lead to heart failure [2, 3] . However, until now, cellular responses to hypoxia/reoxygenation (H/R) are still incompletely understood and little is known about cGMP dynamics in the context of H/R. Aims and methods: It was the aim of this project to study the effects of H/R on cGMP dynamics in mammalian cardiomyocytes. Therefore transgenic mice with cardiomyocyte-specific expression of the cytosolic Förster-resonance energy transfer (FRET)-based cGMP sensor red cGES-DE5 [4] were used. We performed FRET measurements in single adult cardiomyocytes exposed to H/R and additionally used a Langendorff system for FRET measurements in whole heart.
Results:
In single adult cardiomyocytes exposed to H/R, basal cGMP levels were increased. This increase was generated during hypoxia and was maintained during reoxygenation. After H/R PDE3 protein expression as well as activity were significantly downregulated, whereas RNA expression level of PDE3 was not significantly changed. At the same time, protein levels of soluble guanylyl cyclase β-subunit showed a tendency towards downregulation during H/R. Our whole heart measurements indicate that there is also an influence of other cell-types on cGMP dynamics or on cGMP cell-cell transfer since we could show that cGMP levels increase during anoxia and decrease during reoxygenation.
Conclusion:
In conclusion, we found an increase of intracellular cGMP levels in hypoxia. The development of FRET-based cGMP measurements in single cardiomyocytes and whole hearts in the context of H/R should help to distinguish between direct protective effects on cardiomyocytes and indirect mechanisms such as cell-cell interactions in cGMP signaling during and after H/R. This offers great opportunities to dissect the molecular mechanism of cGMP signaling regulation during ischemic injury.
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We have no conflict of interest to declare. We have no commercial associations that might pose a conflict of interest with the submitted abstract. Guanylate cyclases are important drugs targets for several disorders, including cardiovascular, pulmonary and renal diseases. Only hemedependent stimulators and heme-independent activators of soluble guanylate cyclases (sGCs) have been amply studied, although even in this case their mechanism of action is unclear. We have recently described the potential binding site of heme-dependent stimulators [1] . In this study, we are: first, investigating the mechanism of action of these hemedependent stimulators of sGCs, and, second, searching for new modulators of membrane guanylate cyclases (mGCs). In both cases, we are using the recently available structural data for this class of enzymes.
Methods:
Basically, the general procedure includes first comparative modelling of the target protein (based on the satisfaction of spatial restraints), docking of a subset of compounds pertaining to the ZINC-database (Zbc-ZINC Biogenic compounds; 180,313 molecules) to several conformations of the potential "druggable" sites in the proteins of interest, and selection of the compounds with the best score for site specificity. Drugs with poor site and protein specificity are discarded. Molecular dynamics is used for the selection of protein conformations submitted to drug docking (after evaluation of the volume of the cavities during the whole simulation) and to analyze the time-dependent structural changes evoked by the best-scoring compounds. Ligand binding affinities are evaluated by the Linear Interaction Energy (LIE) method [2] .
Results and conclusions:
Molecular dynamics of the catalytic domain of human sGC (both, in its inactive and active conformations) in the presence or absence of YC-1 are underway to identify its possible mechanism of action. On the other hand, different sites (including catalytic and receptor domains) of the atrial natriuretic peptide receptor 1 have been submitted to structure-based virtual screening (SBVS) in order to find new modulators of mGCs. Preliminary results of this screening are shown on Table 3 and Fig. 4 Background: Natriuretic peptide receptor-B (NPR-B; GC-B) stimulation by C-type natriuretic peptide (CNP) causes a lusitropic and negative inotropic response, through cGMP-mediated phospholamban (PLB) and troponin I (TnI) phosphorylation. Despite similar increases in cGMP, these effects are not mimicked by NPR-A (GC-A) stimulation by brain natriuretic peptide (BNP). Thus, the mechanisms of the differential cGMP signalling and compartmentation remain unclear. Objective: Clarify the organization of functional cGMP compartments and the role of phosphodiesterases (PDEs) in both neonatal and adult rat cardiac myocytes.
Methods and Results:
In ventricular strips, NPR-B-stimulation induced a lusitropic response and negative inotropic response that was enhanced by inhibition of PDE3. Fluorescence resonance energy transfer (FRET)-based sensors for cGMP subcellularly targeted to proteins that regulate inotropic responses (TnI and PLB) were constructed. Measurements of subcellular changes in single cardiac myocytes revealed that NPR-A-and NPR-Bstimulation increased cGMP near PLB, whereas only NPR-B-stimulation increased cGMP near TnI. PDE2 and PDE3 regulated cGMP in both compartments. By combining scanning ion conductance microscopy (SICM), FRET and local receptor stimulation, we demonstrate that NPR-B receptors both in the T-tubules and on the cell crests are able to increase cGMP similarly near both TnI and PLB. Conclusions: NPR-A receptors increase cGMP only near PLB and does not modify lusitropic or inotropic responses. The cGMP-mediated lusitropic and negative inotropic responses generated by NPR-B in cardiac myocytes is compartmentalized near both TnI and PLB. The developed targeted sensors are novel tools to characterize the cGMP compartments that regulate inotropic and lusitropic responses.
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Background:
Lung fibrosis is a chronic disease with a median survival of three years. Underlying mechanisms are not fully understood and effective therapies are lacking. During fibrosis, myofibroblasts are responsible for an excessive production and deposition of extracellular matrix (ECM) proteins and collagen. As consequence, functional tissue is replaced by scar tissue. The origin of myofibroblasts remains unresolved and pericytes have been implicated as a source of myofibroblasts. NO-sensitive guanylyl cyclase (NO-GC), the receptor for NO, has been recently shown by our group to be highly expressed in retinal pericytes. Therefore, we hypothesized NO-GC Fig . 4 (Abstract A29). Binding sites of the drugs with the best score in a structure-based virtual screening (SBVS) for modulators of NPRA. a chains A and B of the receptor domain of human NPRA (in a surface representation; mauve and blue) with bound ANP (in a licorice representation; red); (b) chain B (in this view chain A has been eliminated for simplicity) with ANP and the six drugs with the best score (see Table  3 ) in a preliminary SBVS (in sphere representations; green). expression in lung pericytes and a potential modulation of fibrotic processes by the NO/cGMP cascade.
Methods:
To investigate a possible participation of NO-GC in lung fibrosis we used our general KO mice (GCKO). Expression of Cre recombinase under the control of the SMMHC promotor led to deletion of NO-GC in SMC but surprisingly also in lung pericytes; therefore, we used the 'smooth muscle cell-specific' KO mice as model for pericyte-directed NO-GC deletion. Fibrosis was induced by a single dose of bleomycin (2 U/kg) via intratracheal instillation. 21 days after instillation lungs were harvested. Measurements of dry lung weight and collagen content were used to evaluate fibrotic responses. Immunohistochemistry was performed to characterize pericytes and lung fibrosis.
Results:
In fact, NO-GC expression can be detected in lung pericytes by colocalization with established pericyte markers PDGFRβ and desmin. Healthy lungs did not express αSMA, a typical marker of fibrosis. Bleomycin treated mice developed fibrosis shown by an increase in lung dry weight and collagen content. Both parameters were further elevated in GCKO mice and in animals deficient in pericyte-NO-GC compared to control animals. In control mice, fibrotic areas were defined by cells expressing PDGFRβ and αSMA without NO-GC expression. In GCKO, fibrotic areas were bigger and more diffuse compared to control animals.
Conclusion:
Absence of NO-GC leads to a deterioration of bleomycin-induced lung fibrosis in mice. Thus, NO/cGMP signalling appears to be protective in the development of lung fibrosis.
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The 
Introduction:
Sildenafil and tadalafil are phosphodiesterase 5 (PDE5) inhibitors widely used as therapy in erectile dysfunction and pulmonary hypertension. Their mechanism of action is the elevation of intracellular cyclic guanosine monophosphate (cGMP) by inhibiting the break down by PDE5. cGMP regulates different processes like smooth muscle relaxation and platelet aggregation [1] . Binding of cGMP to the allosteric site of PDE5 causes a conformation change in the catalytic site of the enzyme, enhancing the binding affinity of PDE5 inhibitors [2] [3] [4] . Using isolated and/or recombinant PDE5, it has been demonstrated that cGMP can increase the affinity of this enzyme for sildenafil and tadalafil [5, 6] , but none of them investigated the influence of this changed affinity on intracellular concentrations of PDE5 inhibitors.
Objectives:
The aim of this work was to demonstrate that the change of PDE5 affinity for PDE5 inhibitors provoked by cGMP leads to higher intracellular concentrations of these compounds. Platelets -possessing the entire pathway -were used as a cell system. Materials and methods: Isolated and washed platelets were incubated with sildenafil or tadalafil at different concentrations and for a range of time intervals with or without DEA NONO-ate as an NO donor. Intracellular sildenafil and tadalafil concentrations were quantified using ultra performance chromatography coupled to mass spectrometry methods and intracellular cGMP was measured with a commercial ELISA assay.
Results:
Intracellular cGMP concentrations increased when samples were treated with sildenafil with or without DEA NONO-ate (5 μM). Sildenafil was avidly taken up into platelets leading to substantially higher intracellular than extracellular concentrations with up to 4-fold higher concentrations in the DEA NONO-ate treated samples. Regarding time dependency a plateau was reached after 10 min. The results obtained for tadalafil were similar to those for sildenafil aside from some aspects. A plateau was reached only after 30 min, intracellular accumulation was considerably higher than for sildenafil, and the effect of DEA NONO-ate was less pronounced.
Conclusion:
Sildenafil and tadalafil both accumulate extensively inside platelets. cGMP concentrations present in the cell influence accumulation most likely by changing the affinity of PDE5 inhibitors for PDE5.
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Background:
Regulation of gastrointestinal motility is complex and involves both excitatory and inhibitory neurotransmission. A very important inhibitory neurotransmitter is nitric oxide (NO). In the GI tract, NO-sensitive guanylyl cyclase (NO-GC), is the main receptor for NO, which leads to generation of cGMP. It is expressed in several cell types such as smooth muscle cells (SMC) and interstitial cells of Cajal (ICC). Cellspecific knockout mice for NO-GC revealed NO-GC as an intricate modulator of spontaneous contractions in the colon and specified the role of SMC and ICC in the regulation of murine colonic motility.
Methods:
This study focuses on the role of NO-GC in murine colonic motility. We used isometric force studies to record contraction pattern of colonic circular muscle rings from global NO-GC knockout (GCKO) and cell-specific knockout mice lacking NO-GC specifically in SMC or ICC. Moreover, video recordings of whole colon preparations were used to generate spatiotemporal maps, in order to evaluate the contraction pattern and propagation characteristics of the knockout mice. Outflow measurements gave detailed information about the efficiency of the propulsive contractions. Pancreatic cancer has the highest cancer mortality rate of 93%. Only 57% of pancreatic cancer patients live up to 6 months and only 15% of patients live over a year and a half. However, the effective therapies for pancreatic cancer are lacking. T-type calcium channels (transient opening calcium channels) are normally located within the brain, peripheral nervous, cardiovascular, and endocrine systems. Overexpression of Tchannels in different tumor types has recently gained attention; however, the role for these channels in pancreatic cancer is not well explored. NNC 55-0396 is an analog of mibefradil (Ro 40-5967) with higher selectivity, enhanced potency and reduced side effects. It has been suggested that NNC 55-0396 can permeate through the plasma membrane and block T-calcium channels, however, the signaling pathways underlying its anti-cancer activity is unknown (1). Our studies with in four pancreatic cancer cell lines (Pa-TU-8988, Panc-1, YAPC, BxPC-3) showed that T-channel subtype Cav 3.1 (α1G) is expressed in all cell lines, whereas Cav 3.2 (α1H) only in Panc-1. The α1subunit is the primary subunit that forms the transmembrane pore of the channel. NNC 55-0396 treatment inhibited proliferation of all cell lines. The silencing Cav 3.1 by using siRNA CACNA1G in Pa-TU-8988 cells resulted similar proliferation inhibition. Cell cycle analysis in Pa-TU 8988 synchronized cells treated with NNC 55-0396 (5μM) revealed a T-channel blockerinduced G1 arrest. Thus, we further verified the expression of key genes involved in cell cycle regulation. The cyclin-dependent kinases 2 (cdk-2) and 6 (cdk-6) were significantly decreased by 0.56-and 0.38-fold, respectively while the cdk inhibitor p21 (CDKN1A) was markedly increased by 2.5 fold after treating with NNC 55-0396 (5μM, 24 hours). No significant difference was observed in cdk 4 gene expression. Similar results were observed with Western blots of CDK2, 6 and p21 Since the p21WAF1/Cip1 (p21) protein is an inhibitor of cyclin-dependent kinases, we also checked other pancreatic cells and observed that the Tchannel blocker increased p21 expression in all cell lines. The cyclindependent kinase inhibitor p21 is a major effector of the tumor suppressor p53. However, T-Ca 2+ channel blocker promoted p21 expression in both p53-positive (Panc-1, BxPC-3) and p53-deficient (Pa-TU-8988) cells (2) , and inhibited proliferation of all tested cell lines. We propose that p21 can be activated independently of p53 in pancreatic cancer cells. T-type Ca 2+ channel blocker may exerts transcriptional regulation of p21 directly or via either PKG I or HDAC pathways in pancreatic cancer cells. Arterial hypertension is an increasingly prevalent condition that predisposes an individual to increased risk of cardiovascular disease and mortality. Despite the availability of antihypertensive drugs, many patients have high blood pressure that is resistant to current treatments. The discovery that cGMP-dependent protein kinase 1α (PKG1α) intermolecular disulfide formation contributes to oxidant-induced or endotheliumderived hyperpolarisation factor-dependent vasodilation [1, 2] , highlights a new mechanism that could be targeted therapeutically to lower blood pressure in patients resistant to current therapies. Such drugs may also offer a new, complementary first-line therapy against hypertension. Here we developed a novel drug assay to screen a library of small electrophilic compounds, to find those that covalently target cysteine 42 of PKG1α to mimic or induce disulfide activation. 12 candidates identified in this screen were subsequently tested for their ability to relax mesenteric vessels isolated from wild-type mice. Those that successfully relaxed mesenteries were re-tested in vessels from wild-type and concomitantly compared to those isolated from C42S PKG1α knock in (KI) mice. This led to the identification of a hit compound, which we named G1 that induced relaxation of wild-type mesenteric vessels (EC 50 = 3.9 ±0.65uM), but to a lesser extent those isolated from C42S PKG1α KI mice (EC 50 = 37 ±11.4uM). Furthermore, feeding of G1 (20 mg/kg for 4 days) lowered blood pressure in telemetered angiotensin-II hypertensive wild-type mice. This ability of G1 to lower blood pressure was absent in hypertensive C42S PKG1α KI mice, thus confirming selectivity for its mechanism of action. In summary, we have identified the first in a new class of antihypertensive drug that with further development, could be used clinically to lower blood pressure as a first line therapy or perhaps to treat patients resistant to current interventions.
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The authors declare that they do not have a potentially perceived conflict of interest. Our aim is to monitor the dynamic changes of cGMP in specific sub-cellular microdomains in cardiac myocytes. Here, the concentration of cGMP is low, and there are few current cGMP-sensors that can monitor the low cGMP concentrations seen after guanylyl cyclase activation. In the current study, we wanted to construct novel FRET sensors with high affinity for cGMP that can measure temporal and spatial signaling of guanylyl cyclases.
Methods:
We constructed novel cGMP sensors based on cGMP binding domains from Plasmodium falciparum (PfPKG) and human (PKG I and PKG II). The binding domains were sandwiched between FRET pairs, either cyano (CFP) and yellow (Venus) or blue (T-sapphire) and red (Dimer2) fluorescent proteins. To improve affinity and selectivity (against cAMP), mutations in the cGMP-binding pocket improved affinity and also selectivity. All sensors were expressed in HEK293 cells and FRET efficacy was determined either in vitro or in intact cells stimulated with an NO donor (stimulates soluble guanylyl cyclase).
Results:
We designed three sensors with high affinity (~10 nM) for cGMP and high selectivity towards cAMP (up to 1.000 fold). All sensors yielded a large dynamic range (10-20 % change in FRET) and responded to NO-donor in HEK293 cells.
Conclusions:
The new sensors based on modified cGMP binding domains from PKG I has the ability to detect cGMP with high affinity and selectivity. We termed the sensor with highest selectivity "ScGI sensor" (Selective cGMP-dependent protein kinase I sensor) and believe it will be a valuable tool to unravel spatial and temporal cGMP-mediated intracellular signaling in cardiac myocytes. 
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Background:
Although nitroxyl (HNO) is produced endogenously, with pharmacological donors showing broad therapeutic promise, its mechanisms of action is not fully elucidated.
Methods and Results:
Mass spectrometry and site-directed mutagenesis showed that the chemically distinct HNO donors 1-nitrosocyclohexyl acetate or Angeli`s salt each induced disulfides at disparate sites within cGMPdependent protein kinase I-alpha (PKGIα). These included interdisulfide between Cys42 of the two identical subunits of the kinase, as well as a previously unobserved intradisulfide between Cys117 and Cys195 in the high affinity cGMP-binding site. Kinase activity was monitored in cells separately transfected with wildtype (WT), Cys42-Ser or Cys117/195Ser PKGIα that cannot form the inter-or intradisulfide, respectively. This revealed HNO enhanced WT kinase activity, an effect significantly attenuated in inter-or intradisulfide-deficient PKGIα. Cys42/117/195Ser PKGIα was completely resistant to HNOinduced activation. To investigate whether the intradisulfide modulates cGMP binding, real-time imaging was performed in vascular smooth muscle cells expressing a FRET-biosensor comprising the cGMP-binding sites of PKGIα. HNO induced FRET changes similar to those elicited by an increase of cGMP, suggesting that HNO-induced intradisulfide formation is associated with activation of PKGIα. Consistent with the intradisulfide lowering affinity for its classical second messenger activator, cGMP was unable to potentiate HNOintradisulfide induced PKGIα activity. Intradisulfide formation in PKGIα correlated with enhanced HNO-mediated vasorelaxation in mesenteric arteries in vitro and arteriolar dilation in vivo in mice.
Conclusion:
We conclude that HNO induces an intradisulfide in the high affinity cGMP-binding site of PKGIα, inducing the same effect as cGMP binding, namely kinase activation and thus vasorelaxation. # equal contribution Cyclic GMP regulates multiple functions in the cardiovascular system. It is generally accepted that vascular smooth muscle cells (VSMCs) can generate cGMP through NO-activated soluble guanylate cyclase as well as transmembrane guanylate cyclases GC-A and GC-B that are stimulated by atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP), respectively. Studies with atherosclerotic mice in which either NOactivated guanylate cyclase or cGMP-dependent protein kinase I had been deleted suggest that cGMP signaling regulates dynamic changes of VSMC growth and phenotype (contractile vs. synthetic) during vascular remodeling. However, the distribution and function of NO-, ANP-, and CNP-responsive cells in a given population of VSMCs is not clear. Here, we used transgenic cGMP sensor mice that express the fluorescence resonance energy transfer-based cGMP sensor cGi500 to characterize cGMP responses in live VSMC populations at the singe-cell level. In primary VSMCs isolated from ubiquitously expressing cGi500 mice, we observed a strong heterogeneity of cGMP signals triggered by ANP, CNP, or the NOreleasing compound DEA/NO. Interestingly, differential cGMP responses were associated with specific VSMC phenotypes. Contractile VSMCs (defined by strong expression of αSMA and SM22α) responded stronger to ANP than to CNP, while synthetic VSMCs (defined by weak expression of αSMA and SM22α) responded stronger to CNP than to ANP. Passaging or growth on fibronectin, maneuvers known to promote the synthetic VSMC phenotype, increased the fraction of CNP-responsive cells. To confirm that the CNP-preferring cells originate from smooth muscle cells, we isolated VSMCs from transgenic mice that expressed the cGi500 sensor specifically in smooth muscle cells [SM22Cre x R26-CAG-mT/cGi500(L2)]. These cultures also contained a heterogeneous population of ANP-and CNP-preferring cells demonstrating that different VSMC phenotypes vary in their combination of cGMP signaling components. In line with this concept, experiments with VSMCs expressing β-galactosidase under the control of the GC-B promoter indicated that expression of the CNP receptor parallels the development of the synthetic VSMC phenotype during cell culture. To test the relevance of our in vitro findings for the in vivo situation, we measured cGMP signals in aortae of healthy cGMP sensor mice. These aortae showed cGMP responses to ANP and NO, but not to CNP, supporting the hypothesis that CNP-responding synthetic VSMCs develop in vivo only under pathologic conditions such as atherosclerosis. In the future, we will employ biosensor technology to further investigate the link between CNP-induced cGMP signaling, VSMC plasticity and vascular disease under close-to-native conditions to gain novel insights into human cardiovascular disease states.
Funding
This work was supported by DFG grant FOR 2060.
Competing interest
The authors declare no competing financial interests.
A39
A new look at cGMP signaling, shear stress, and thrombosis Susanne Feil # equal contribution It is well known that NO supplied by the endothelium activates NOsensitive guanylate cyclase (NO-GC) in platelets, resulting in an increase in intraplatelet cGMP. However, the spatiotemporal dynamics of cGMP signals in platelets and their functional relevance during hemostasis and thrombosis are largely unknown. Here, we used FRET-based cGMP sensor mice for visualization of platelet cGMP signals in real time during thrombus formation ex vivo and in vivo. The cGMP concentration was then correlated with functional parameters such as platelet aggregation and thrombus growth. As expected, NO triggered strong cGMP elevations in platelet thrombi formed under flow in vitro. Surprisingly, we found that NO-induced cGMP signals in platelets were dramatically increased by fluid flow/shear stress. Simultaneous measurements of cGMP and Ca 2+ revealed that the concentrations of these two second messengers had an inverse relationship. In the presence of NO, application of flow increased cGMP and suppressed Ca 2+ signals. Furthermore, cGMP inhibited platelet adhesion to fibrinogen and fibronectin in vitro. To test the in vivo relevance of our findings, we induced thrombosis in plateletspecific cGMP sensor mice by mechanical or laser-induced injury of cremaster arterioles and monitored cGMP during thrombus formation by intravital FRET imaging. These experiments showed that cGMP was indeed elevated in platelets during thrombus growth in vivo. Experiments with platelet-specific NO-GC knockout mice validated the FRET/cGMP measurements and showed that flowmediated cGMP signaling limits thrombosis. Taken together, this study has discovered NO/cGMP signaling as a new mode of platelet mechanotransduction. We propose a revised model for the role of cGMP signaling in thrombosis. In this model an increase in shear stress during thrombus formation acts as an auto-regulatory brake to prevent thrombus overgrowth and vessel occlusion via an increase in cGMP followed by a decrease in the intraplatelet Ca 2+ concentration.
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Mechanisms associated with cGMP-dependent activation of Background: Protozoan parasites of the subphylum Apicomplexa are significant threats to human and animal health. Malaria is still one of the most threatening infectious diseases worldwide [5, 8] . In particular, treatment of malaria has been hampered by drug resistance. Therefore, the development of innovative therapies with novel drug targets is needed. The most dangerous and deadliest variant of malaria is caused by protozoans of the Plasmodium falciparum, which are transmitted by the female Anopheles mosquitoes. Previous studies revealed that P. falciparum cGMP-dependent protein kinase (PfPKG) has three functional cGMP (CNB-A/B/D) and one degenerate (CNB-C) binding site [2, 3] . PfPKG is crucial for both sexual and asexual proliferation in the mosquito and the human host [1, 5, 7, 8] . Overall sequence and domain organisation of PfPKG significantly differ from mammalian PKG representing a strong drug target for malaria. However, the regulation mechanisms of PfPKG are largely unknown. Our previous studies demonstrated that the C-terminal CNB-D is most important for the activation of PfPKG [3, 4] . Most of protein kinases have an N-terminal amphipathic helix (A-helix) shielding a hydrophobic surface of the catalytic domain. Although the A-helix has a highly conserved structural motif of serine/threonine kinases, its functional role in activation and regulation is not known. The crystal structure of PfPKG reveals that the αC-helix of the CNB-D corresponds to this structural motif. Therefore, we focused in particular on different CNBs and the catalytic domain to investigate the activation mechanism of PfPKG.
Results:
To investigate the activation mechanism of PfPKG, we studied cGMP binding and activation of various deletion constructs using fluorescence polarization (FP) and a microfluidic mobility-shift assay (MSA). Our results showed differences in the activation mechanism of PfPKG compared to mammalian PKG. Strikingly, our measurements showed that a deletion construct (residues 401-853) only containing CNB-D and catalytic domain remains inactive without cGMP and becomes active in the presence of cGMP despite the missing an N-terminal autoinhibitory sequence (AS). Furthermore, several deletion constructs of the PfPKG were generated, in which the individual CNBs were sequentially deleted: PfPKG 32-853 (without AS), PfPKG 158-853 (without AS and CNB-A), PfPKG 275-853 (without AS and CNB-A/B) and PfPKG 401-853 (CNB-D with kinase domain). Analogously to PfPKG 401-853, all deletion constructs revealed a low basal activity and can be activated 20-25-fold by cGMP suggesting that inhibition of activity may not depend on the interaction between the AS and the catalytic domain. While these deletion constructs showed similar activation constants (K A about 300 nM) compared to the full length PfPKG, the Hill's coefficient changed from 1.7 (PfPKG 32-853) to 0.7 (PfPKG 401-853) indicating that CNB-A and CNB-B are required for positive cooperativity. Structural comparison of PfPKG in inactive and active conformations suggested that three amino acids are crucial in stabilizing different conformation of the αC-helix. The inactive conformation showed that an arginine (R528) of the αC-helix forms a hydrogen bond with an aspartate (D597) in the catalytic domain. The cGMP binding to the CNB-D displaces R528 towards the cGMP binding pocket and R528 interacts with a tyrosine residue (Y480) instead forming a stable salt bridge. Our data show that mutating these residues in the deletion mutant (PfPKG 401-853) increases activation constant without changing its affinity for cGMP. In comparison to wild type (PfPKG 401-853), single mutant constructs (Y480F, R528K and D597N) have similar affinities (EC 50 about 40 nM) for cGMP. However, Y480F mutation showed a 5-fold increased K A -value (about 1500 nM) and R528K as well as D597N a 6-fold decreased K A -value (about 70 nM) compared to wild type. In contrast to wild type (PfPKG 401-853), R528K has a great impact on the specific activity (about 0.3 vs. 5-6 U/mg).
Conclusion:
Our data highlight the critical role of the CNB-D domain in activation and regulation of PfPKG. Furthermore, CNB-D is essential for the function and the stability of the catalytic domain. cGMP binding to the CNB-D domain causes a conformational change in particular in the αC-helix, which keeps the catalytic domain to an active conformation. A unique salt bridge between R528 of the αC-helix and Y480 of the CNB-D domain stabilizes PfPKG in an active conformation. Our results clearly demonstrate differences in the activation mechanisms between PfPKG and human PKG suggesting that PfPKG can be differentially targeted. PAH is a chronic condition with a poor prognosis characterized by increased pulmonary vascular resistance. Riociguat, a soluble guanylate cyclase stimulator, is the first member of this novel class of PAH therapies. In the 12-week PATENT-1 study, riociguat significantly improved 6-minute walking distance (6MWD), and other secondary endpoints in patients with PAH. We present analyses from the longterm PATENT-2 extension study and analyses of correlation between efficacy endpoints and long-term outcomes.
Methods:
PAH patients who were treatment-naïve or pretreated with endothelin receptor antagonists or prostanoids entered PATENT-2 after completing PATENT-1 without ongoing riociguat-related serious adverse events (SAEs). All patients received riociguat individually adjusted up to 2.5 mg three times daily. Primary endpoints were safety and tolerability; secondary endpoints included 6MWD, World Health Organization functional class (WHO FC), N-terminal prohormone of brain natriuretic peptide (NTproBNP), survival, and clinical worsening-free survival. Correlation between efficacy parameters and long-term outcomes was assessed using Kaplan-Meier analyses and a Cox proportionalhazards regression model.
Results:
Of 405 patients completing PATENT-1, 396 (98%) entered PATENT-2. At this cut-off (March 2014), 275 (69%) patients were ongoing, 307 (78%) had received ≥2 years of treatment, and 13 (3%) had switched to the commercial drug. At 2 years of PATENT-2, 258/307 (84%) patients were receiving the maximum riociguat dose of 2.5 mg tid, 31/ 307 (10%) were receiving 2 mg tid, 12/307 (4%) were receiving 1.5 mg tid, 3/307 (1%) were receiving 1 mg tid, and 3/307 (1%) were receiving 0.5 mg tid. Riociguat was well tolerated; 11% of patients withdrew due to adverse events (AEs). There were 13 (3%) drugrelated SAEs of syncope and 4 (1%) drug-related SAEs of pulmonary bleeding. All SAEs reported were within the range of the known safety profile for riociguat. At 2 years, mean±SD 6MWD increased from PATENT-1 baseline by +47±85 m (n=296) and WHO FC improved/stabilized/worsened in 33/58/9% of patients (n=306). At 2 years, survival was 93% and 17% of former therapy-naïve patients were receiving additional PAH therapy. Measurements of 6MWD, WHO FC, and NT-proBNP at baseline and after 12 weeks of treatment with riociguat correlated significantly with long-term survival and clinical worsening-free survival.
Conclusions:
Riociguat has a good long-term safety profile and shows sustained clinical effect for up to 2 years in PAH patients. The correlation of 6MWD, WHO FC, and NT-proBNP with long-term survival and clinical worsening-free survival emphasizes the prognostic value of 6MWD, WHO FC, and NT-proBNP for PAH patients.
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Background:
The NO/cGMP cascade is essential for the regulation of many physiological functions in the pulmonary system. NO-sensitive guanylyl cyclase (NO-GC) has traditionally been purified from lung due to its very high expression level compared to other organs. Up to date the exact identity of cell types expressing NO-GC in the lung are unclear.
Methods:
We used immunohistochemistry to localize NO-GC in perfusion-fixed mouse lung using a home-made antibody against the β 1 subunit of NO-GC. Global NO-GC knockout (GCKO) and cell-specific models were used to prove the specificity of the immuno-signals. Several markers specific for lung cells, e.g. smooth muscle cells, fibroblasts, pericytes were used. In addition, we used Cre recombinase-mediated, cell-specific expression of the reporter dye tdTomato. Results and Conclusion: NO-GC is expressed in bronchial and vascular smooth muscle cells indicated by co-localization with the smooth muscle cell marker αSMA. In addition, NO-GC is also strongly expressed in pericytes as determined by co-staining with platelet-derived growth factor receptor ß (PDGFRß). Pericytic expression of NO-GC was corroborated by the use of another pericyte marker, desmin. These findings were confirmed with animals expressing the fluorescent dye tdTomato. NO-GC is co-localized with tdTomato expressed under the control of PDGFRß-and NG2-promotor, both markers for pericytes. Surprisingly, a subgroup of these NO-GC-positive pericytes also express smooth muscle myosin heavy chain (SMMHC) thought to be specific for smooth muscle cells. In conclusion, NO-GC is expressed in SMC and pericytes of the lung.
were further treated with 1 mM 8-Br-cGMP to activate the cGKI signalling. In our model, we confirm previously published effects of high glucose concentrations on Thrombospondin-1 (TSP-1) expression, an important regulator of transforming growth factor (TGF)-β. [4] TSP-1 expression is upregulated under high glucose conditions, but additional incubation with 8-Br-cGMP retains the protein expression equally to normal glucose conditions. Moreover, we show the same effect on Smad-2 expression, a protein which acts as a transcription factor and regulates the expression of extracellular matrix proteins like fibronectin. This could be a first hint that the activation of cGKI might have compensative effects under high glucose conditions. To gain a more detailed insight into the cellular processes under high glucose conditions, we are using a proteomic approach with LC/MS. With this tool, we are able to identify and quantify over 2000 proteins in one cell lysate sample and to compare the proteome from differently treated cells.
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Iα in nociceptive neurons induces a long-term hyperexcitability that causes chronic pain in diseases such as nerve inflammation, ischemia, and metastatic bone cancer [5] [6] [7] . A recent study showed that a balanol like compound, N46, inhibits PKG Iα with high potency and selectivity (Fig. 5 ) and attenuates thermal hyperalgelia and osteoarthritic pain in rats [8] . However, little is known about the molecular details of PKG Iα and N46 interaction.
Results:
To understand the molecular basis of high potency and selectivity of N46, we measured its inhibition constants for PKG Iα catalytic (C) domain and determined their co-crystal structure at 2.5 Å resolution. Our measurements using Kinase-Glo Luminescent Assay show that N46 inhibits PKG Iα C with an IC 50 value of 3.7 nM (using BPDEtide as a substrate) while it inhibits PKA Cα with 360 nM (using Kemptide). The crystal structure of PKG Iα C:N46 complex reveals that N46 binds to an elongated pocket that extends from the inner edge to the outer rim of the active site of the active site within the Cdomain. In particular, N46 interacts with Gly348 at the glycine rich loop and bulky residues at the inner surface of the αB helix mainly through nonpolar interactions. Our structural model of the cAMP dependent protein kinase (PKA) Cα docked with N46 shows that a serine residue (Ser53) replaces Gly348 in the glycine rich loop and may cause steric hindrance thus reducing interaction. The model also shows that the same region at the αB helix in PKA Cα has less bulky residues making no contact with N46.
Conclusion:
Our activation data show that N46 inhibits PKG Iα C with high affinity and selectivity over PKA Cα. Our co-crystal structure of the PKG Iα C and N46 explains high potency and selectivity of N46 for PKG Iα and provides a starting point for structure guided design of PKG I selective inhibitors. As a central part of the NO/cGMP signaling pathway soluble guanylate cyclase (sGC) has become a promising therapeutic target in the treatment of cardiovascular diseases [1] and is thus subject of intensive research. In the course of studies on bioactivation of the anti-anginal drug nitroglycerin in blood vessels we performed co-incubation experiments of purified sGC from bovine lung with cytosols from porcine coronary arteries. Cytosolic preparations considerably diminished NO-stimulated sGC activity (Fig. 6a) . This effect persisted in the presence of the phospodiesterase inhibitor isobutylmethylxanthine, a protease inhibitor cocktail, and superoxide dismutase, excluding cGMP hydrolysis, proteolysis of sGC, and NO inactivation by superoxide as culprits. Spectroscopic analysis of cytosols revealed the presence a heme-containing protein with characteristic Soret and α/β bands (Fig. 6b) . Using Western blot and LC-MS/MS analysis we identified the protein as hemoglobin, which is known to effectively scavenge NO [2] . Heme-mediated NO scavenging by cytosolic preparations was confirmed with an NO-sensitive electrode (Fig .   Fig. 5 (Abstract A45). The crystal structure of the PKG I C:N46 complex explains high selectivity of N46 for PKG Iα. ADP to ATP conversion curves in the presence of N46 are shown for both PKG I C and PKA Cα on the top and the crystal structure of the PKG I C domain bound with N46 on the bottom. The structure of the PKG I C:N46 complex is shown in a surface representation. The zoomed-in view highlights N46 bound within the extended pocket formed between the small and large lobes. The surface is colored according to the contact electrostatic potential calculated with APBS [9] . Positively charged areas are shown in blue and negatively charged areas are in red. Each data points were measured in duplicate using KinaseGlo Luminescent Assay. Error bars denote SEM 6c). Removal of hemoglobin by haptoglobin affinity chromatography revealed an unexpected increase of NO-stimulated sGC activity by cytosols (Fig. 6d) . The effect was dependent on the amount of cytosolic protein added (Fig. 6e) , precipitable by ammonium sulfate (Fig. 6f) , and sensitive to heat and organic solvents. Preliminary results indicate that this protein, termed sGCactivating factor (sGC-AF) can be recovered by gel filtration. Work on isolation and identification of sGC-AF is ongoing in our laboratory. Our findings demonstrate expression of an as yet unidentified protein in porcine coronary arteries that activates sGC, resulting in increased v max of the maximally NO-stimulated enzyme. cGMP is known as a second messenger plays a crucial role in penile erection and vascular homeostasis. We previously reported that cGMP acts the signal mediator in 67-kDa laminin receptor-dependent multiple myeloma cell death 1 . Here we show cGMP induction drastically suppressed CSC properties in three different PDAC cell lines including Panc-1, Miapaca-2 and BxPC-3 cells. Our microarray analysis showed cGMP-induction suppressed FOXO3 (see Fig. 7a ). We also showed FOXO3 are strongly expressed in CD44 + cells 2 . Surprisingly, FOXO3, known as the tumour suppressor plays the crucial role in the maintenance of CSC properties and FOXO3 knock down strongly suppressed CSC properties by downregulation of CD44, the essential protein for CSC properties (see Fig. 7b, c) . The same results were obtained in vivo 2 .
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Conclusion:
Considering the FOXO3 knock out mice did not change survival period, cGMP induction and FOXO3 suppression could be the novel strategies for PDAC therapy.
Conflict of interest
The authors declare that they do not have a potentially perceived conflict of interest. (ALDH2) catalyzes vascular bioactivation of the antianginal drug nitroglycerin (GTN), resulting in 3´,5´-cyclic guanosine monophosphate (cGMP)-mediated vasodilation through activation of soluble guanylate cyclase (sGC). We have previously shown that a minor reaction of ALDH2-catalyzed GTN bioconversion, accounting for about 5% of the main clearance-based turnover yielding inorganic nitrite, results in direct nitric oxide (NO) formation and concluded that this minor pathway could provide the link between vascular GTN metabolism and activation of sGC [1] . However, the biological significance of NO formation by purified ALDH2 is questioned by the persistent failure to detect release of NO in vascular tissue and cells exposed to therapeutically relevant GTN concentrations (<1 μM). To address this issue, we took advantage of a novel, highly sensitive genetically encoded fluorescent NO probe (C-geNOp) that enables real-time monitoring of intracellular NO formation in cultured vascular smooth muscle cells (VSMC) expressing either wildtype ALDH2 or a mutant (C301S/C303S ALDH2) that reduces GTN to NO but lacks clearance-based GTN denitration activity. Addition of 1 μM GTN to VSMC expressing either wild-type or C301S/C303S ALDH2 resulted in a pronounced increase in intracellular NO, with maximal concentrations of 7 and 17 nM, respectively (Fig. 8a) . In VSMC expressing C301S/C303S ALDH2 NO formation was detectable at therapeutically relevant submicromolar concentrations (10 nM -1 μM) of the nitrate (Fig.  8b) . The selective ALDH2 inhibitor daidzin (0.2 mM) completely inhibited GTN-derived NO formation in a rapid and reversible manner (Fig. 8c) . Formation of GTN-derived NO correlated well with activation of purified sGC in VSMC lysates as well as cGMP accumulation in cultured porcine aortic endothelial cells that had been infected with wild-type or C301S/C303S ALDH2 (Fig. 8d ). Our findings demonstrate that ALDH2-catalyzed NO formation is necessary and sufficient for vascular bioactivation of GTN.
Diastolic heart failure, often referred to as HFpEF (heart failure with preserved ejection fraction) accounts for about 50% of heart failure cases. Currently, there is no good treatment for this condition. Changes associated with HFpEF are impaired left ventricular (LV) filling, increased LV stiffness and altered expression and phosphorylation of the elastic sarcomeric protein titin. The main function of titin is to keep the structural integrity of the sarcomere intact, but also function as an elastic spring, contributing to passive tension development within the myocytes. Protein kinase G (PKG) has earlier been shown to phosphorylate titin and decrease passive stiffness in human myofibrils, thus allowing more compliant cardiomyocytes. PKG can be activated by cGMP increased either by nitric oxide (NO) through the activation of soluble guanylyl cyclase (sGC) or by the natriuretic peptides (NPs) through the activation of the particulate guanylyl cyclases NPR-A (GC-A) or NPR-B (GC-B). The aim of this study was to determine which receptor-mediated signaling pathways induce PKGdependent titin phosphorylation and reduce passive force development. Cyclic GMP levels, titin phosphorylation, phosphomapping of the titin protein and passive tension were performed in isolated rat cardiomyocytes. C-type NP (CNP), stimulating NPR-B, brain NP (BNP) stimulating NPR-A and SNAP (NO donor) stimulating sGC all increased cGMP. However, only CNP increased titin phosphorylation and decreased passive tension in single cardiomyocytes. Thus, despite increasing cGMP, activating NPR-A or sGC did not reduce cardiomyocyte stiffness, whereas NPR-B activation did. This indicates compartmentation of the different signaling pathways increasing cGMP. Further, our results suggest NPR-B as a potential target to improve LV filling by decreasing LV stiffness in HFpEF patients. Drugging cancer metastases, extremely deadly diseases, has been on high demand but still challenging. Metastasis is a step-wise complex phenomenon including dynamic physiological alternations of both cancers and host. Cancers set up a favorable environment (soil) in distant organs for disseminated cancer cells (seeds) to efficiently metastasize: pre-metastatic niche hypothesis. Pre-metastatic niche is a possible target for targeting metastasis. We have previously reported that atrial natriuretic peptide (ANP), an endogenous peptide produced by the heart, inhibits hematogenous cancer metastasis through vascular endothelial cells. We showed that ANP inhibits the tumor cell adhesion to the vascular endothelium by suppressing E-selectin expression, which has a central role in the adhesion of tumor cells to endothelial cells. In this study, we show that ANP suppresses premetastatic niche formation and following metastasis when pharmacologically supplied in tumor-bearing mice. ANP administration reduced the lung metastasis in the mouse models of 4T1 breast cancer and colon26 cancer. Comprehensive RNA-seq analyses using the 4T1 and Lewis Lung Carcinoma (LLC) models demonstrated that gene expression changes characteristics of pre-metastatic niche in the lung were suppressed by ANP treatment. The lung of mice overexpressing GC-A, a receptor for ANP, in endothelial cells, was resistant to pre-metastatic niche formation than the WT lung. Neither ANP administration nor GC-A overexpression had a hazardous effect on the lung gene expressions in a cancer-free condition. In summary, we showed that the endothelial ANP-GC-A signaling attenuates pre-metastatic niche formation in the lung in a context-specific manner.
Conclusion:
Altogether, we concluded that ANP-GC-A signaling as a promising target for controlling hematogenous cancer metastasis and premetastatic niche formation in various types of cancers. Axonal branching is essential for correct formation of neuronal networks and subsequent transmission of information throughout the body. It is well known that a cGMP signaling cascade consisting of C-type natriuretic peptide (CNP), guanylate cyclase B (GC-B, also known as Npr2) and cGMP-dependent protein kinase I (cGKI) is crucial for axon bifurcation of dorsal root ganglia (DRG) sensory neurons and cranial sensory ganglia neurons during mouse embryonic development. In this study, we investigated (1) whether other components of the cGMP signaling pathway, namely phosphodiesterases (PDEs) and the natriuretic peptide "clearance" receptor Npr3, are also involved in the bifurcation of embryonic DRG neurons and (2) whether CNP-evoked increase of cGMP regulates the intracellular Ca 2+ level in DRG neurons. RT-PCR screens, in situ hybridization, and fluorescence resonance energy transfer-based live-cell cGMP imaging revealed PDE2A as the major enzyme responsible for the degradation of CNP-induced cGMP in embryonic DRG neurons. Interestingly, cGMP measurements and DiI labeling of PDE2A knockout embryos indicated that an elevated cGMP level does not disturb axon bifurcation of DRG neurons. Npr3 is expressed in cells of the roof and floor plate of the spinal cord as well as in the dorsal roots of E12.5 mouse embryos. Npr3 likely acts as a clearance receptor for CNP and might, therefore, lower the activity of the CNP/GC-B/cGMP cascade in DRGs. In the absence of Npr3, and presumably higher cGMP levels in DRG neurons, a small proportion of sensory axons showed deficits in bifurcation by turning either in rostral or caudal direction, while most axons branched normally. Fura-2-based Ca 2+ imaging revealed that acetylcholine (ACh) and ATP induce Ca 2+ transients in somata and growth cones of E12.5 DRG neurons, respectively. Simultaneous imaging of cGMP and Ca 2+ signals showed that the ACh/ATP-induced Ca 2+ transients were strongly suppressed by CNP-induced cGMP. The suppressive effect of cGMP on agonist-induced Ca 2+ signals was absent in DRG neurons of cGKI knockout mice demonstrating that the cGMP/Ca 2+ crosstalk is mediated by cGKI. Altogether, our study indicates that DRG sensory axon bifurcation tolerates increased cGMP levels in PDE2A or Npr3 knockout mice. Furthermore, we discovered a crosstalk between cGMP and Ca 2+ signaling in embryonic DRG neurons that might provide a mechanistic basis for axon bifurcation.
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Both activating mutations in fibroblast growth factor receptor 3 (FGFR3) and inactivating mutations of guanylyl cyclase B (GC-B), also called NPRB or NPR2, cause human dwarfism. Reciprocal regulation of the two pathways has been reported, but how FGFR3 inhibits GC-B is not known. Here, we demonstrate that FGF2 stimulation of FGFR3 causes a rapid, potent, and reversible inhibition of endogenous GC-B enzymatic activity in rat chondrosarcoma cells. FGF2 concomitantly reduced the phosphate content and enzymatic activity of GC-B, and the serine and threonine phosphatase inhibitor, cantharidin, blocked the FGF2-dependent reduction in the enzymatic activity of GC-B. A mutated form of GC-B containing glutamate substitutions for all confirmed and putative phosphorylation sites, such that it cannot be inactivated by dephosphorylation, was not inactivated by FGF2. We conclude that FGF2 activation of FGFR3 inactivates GC-B by a reversible dephosphorylation mechanism and suggest that dephosphorylation is a universal inactivation mechanism commonly employed by natriuretic peptide-stimulated guanylyl cyclase receptors.
A54
Prevention of Guanylyl Cyclase-B dephosphorylation increases long bone content, density, and strength Jerid W. Robinson , was created that has a longer appendicular skeleton. Here, we show that GC-B 7E/7E mice have 30% more trabecular bone volume and number, 10% greater cortical bone thickness and area, and 20% more bone mineral density at 9 weeks compared to GC-B WT/WT mice. 3-point bending assays demonstrated that 9 week bones from GC-B 7E/7E mice have 35% increased strength and stiffness and 65% increased toughness compared to wildtype mice, all of which can be attributed to the increased cortical bone. At 16 weeks, cortical area and bone mineral density are still 14% and 22% greater in GC-B 7E/7E mice. However, no difference in trabecular bone volume and number was observed between the two mouse lines at 16 weeks, due to GC-B 7E/7E trabecular bone loss. Why the trabecular bone increases observed at 9 weeks are absent at 16 weeks is not known. These data indicate that blocking GC-B dephosphorylation and inactivation increases cortical and trabecular content, density, stiffness, and strength of long bones at 9 weeks. At 16 weeks the cortical gains are diminished and the trabecular gains are lost. We suggest that therapeutics that increase GC-B phosphorylation may decrease fracture healing time and/or prevent post-menopausal osteoporotic bone loss. Some of the diatomic diffusible molecules, like O2, CO and NO are involve in vital biochemical processes and are classified among the indispensable signaling molecules in all kingdoms of life. Heme-nitric oxide/oxygen binding (H-NOX) domain is found either as a standalone protein consisting of approximately 200 amino acids in length or fused to other domains within larger proteins, such as in soluble guanylate cyclase (sGC) and is conserved across eukaryotes and bacteria. sGC-related proteins consist if a heme-binding N-terminal domain (H-NOX) that regulates the catalytic site located in the Cterminal end of the protein. sGC is an heterodimer, comprising by an α1 or α2 subunit combined with β1 subunit catalyzing the conversion of GTP to cGMP. Within sGC, the H-NOX domain in the β1 subunit functions as a sensor for the diffusible signaling agent nitric oxide (NO). In the vasculature, NO increases the activity of sGC by several hundred fold, and results in vasodilation and inhibition of platelet aggregation. Oxidative stress is the key-factor for heme loss of sGC and consequently, the inability of NO activation. This condition leads the enzyme to degradation and as a result the NO signaling pathway is disrupted. Several chemical compounds like cinaciguat (BAY 58-2667), are heme-independent activators which protects sGC from proteasomal degradation. However, the critical determinants of the gas filtering and the coordination to the iron(II) heme are still not completely elucidated. In the present study we investigate the conformational and the electronic properties of the HNOX domain from Nostoc sp. which exhibits 35% sequence homology with the corresponding one from human sGC. For the structural and dynamic characterization of the protein during the Fe(II) oxidation state, we performed 2D and 3D homo-and heteronuclear NMR experiments in solution as well as UV-visible spectroscopy. Furthermore, we conducted experiments in order to examine the changes upon the heme molecule after the interaction with chemical compounds and oxidizing agents (NO, BAY 58-2667, ODQ). The manner by which the oxidation status of Fe(II)-Protoporphyrin IX prosthetic group affect the structure and the dynamical behavior of HNOX domain will allow us to gain considerable information regarding the regulation of sGC activation/stimulation and will ultimately allow the rational design of ligands interacting in a largely predictable way with sGC.
Conclusions:
In summary, our computational in silico ligand similarity scoring model has identified the GluK2/5 kainate receptor as a potential molecular target for extracellular cGMP, a finding subsequently supported in in vitro biochemical and functional assays. However, in vivo studies are needed to further confirm the identity of the GluK2/5 kainate receptor as a target of extracellular cGMP in relevant animal models.
responses via the modulation of the hypothalamic-pituitary-adrenal (HPA) axis. However, the underlying mechanisms including the cell types and cGMP effectors involved are largely unknown. To shed light on the role of cGKI in stress responses, we studied two conditional cGKI mouse models, (1) mice lacking cGKI in the nervous system, which were generated using a Nestin-Cre line (cGKI-brain-KO mice), and (2) mice, in which cGKI expression was abolished from all cells except smooth muscle cells (cGKI-SM-rescue mice). We exposed cGKI mutant and control mice to different stress types and monitored stress hormone levels by immunoassays, core body temperature by telemetry and brown adipose tissue (BAT) activity, indirectly, by [
18 F]FDG PET imaging. We detected cGKI expression in distinct regions of the hypothalamus, pituitary and adrenal gland, as well as in vessels and nerve bundles of BAT. Interestingly, we found abundant expression of cGKI in fibroblast-like cells evenly scattered between the steroidogenic cells of the adrenal cortex and between brown adipocytes in BAT. Injection of the "immunological stressor" interleukin-1β elicited increased plasma concentrations of adrenocorticotrophic hormone (ACTH) and corticosterone (CORT). While cGKI-brain-KO mice had similar levels of ACTH and CORT as controls, cGKI-SMrescue mice showed significantly higher ACTH and, surprisingly, lower CORT levels than control mice. Compared to controls, CORT release after direct injection of ACTH was attenuated in cGKI-SMrescue mice, suggesting reduced ACTH sensitivity and/or steroidogenic capacity of their adrenal glands. Cold-stress-induced thermoregulation was also defective in cGKI mutant mice. cGKIbrain-KO mice were unable to maintain their core body temperature when subjected to cold-stress at 4°C. PET imaging of cold-stressed cGKI-brain-KO mice revealed reduced [
18 F]FDG uptake in BAT compared to controls, indicating a dysfunction of their BAT. In sum, this study demonstrates the important roles of cGKI in stress responses in mice. Our data suggest that cGKI is mandatory in non-neuronal/Nestinnegative and neuronal/Nestin-positive cells for a proper stress response in the HPA axis and BAT, respectively.
